Icalcaprant is under clinical development by Cerevel Therapeutics and currently in Phase I for Bipolar I Disorder.

Best Stocks for 10 Years. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the ...

Bristol-Myers Squibb has rebounded strongly in 2024, driven by key drug approvals and positive financial performance. See why ...

The complaint alleged that AbbVie treated the doctors, who are experts in Botox and Juvederm, to “extravagant pleasure trips.” The UCPMP, which was amended in March 2024 to make compliance mandatory, ...

The global antiviral drugs market is poised for consistent growth, projected to expand at a compound annual growth rate (CAGR ...

We recently compiled a list of the 10 Best Dividend Growth Stocks to Buy and Hold in 2025. In this article, we are going to ...

For example, the AbbVie Inc. (NYSE:ABBV) share price has soared 101% in the last half decade. Most would be very happy with ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.01 which represents a decrease of $-1.19 or -0.66% from the prior close of $179.2. The stock opened at $177.92 and touched a low of ...

This was the stock's second consecutive day of losses.

AbbVie Healthcare India Pvt. Ltd. found breaching UCPMP by sponsoring international trips for doctors, facing reprimand and ...

The stock's fall snapped a three-day winning streak.

AbbVie (NYSE: ABBV) recently announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult ...